Sponsor | Therapy (delivery route) | Indication | ClinicalTrial.gov identifier (phase, allocation) | Combination | Opened | Status |
---|---|---|---|---|---|---|
Antibodies | ||||||
 Duke University | DC with GITRL/anti-CTLA-4 mAb mRNA (i.n.) | Metastatic melanoma | NCT01216436 (I) | Melanoma TAA mRNA transfected DCs | 2010 | Terminated (lack of personnel) |
Immunomodulators | ||||||
 Cytokines | ||||||
  Medimmune LLC, Moderna TX Inc. | LNP with IL-12 mRNA (i.t.) | Solid tumors | NCT03946800 (I) | Durvalumab | 2019 | Recruiting |
  Moderna TX Inc., AstraZeneca | LNP with OX40L, IL-23 and IL-36γ mRNA (i.t.) | Relapsed/refractory solid tumor malignancies or lymphoma, TNBC, HNSCC, Non-Hodgkin lymphoma, urothelial cancer | NCT03739931 (I) | Durvalumab | 2018 | Recruiting [182] |
  Sanofi, BioNTech SE | scIL-12, IL-15sushi, IFNα and GM-CSF mRNA (i.t.) | Metastatic neoplasms | NCT03871348 (II, non-randomized) | Cemiplimab | 2019 | Recruiting |
 Stimulatory ligands and receptors | ||||||
  eTheRNA Immunotherapies Nv. | TriMix (CD70, CD40L, caTLR4) mRNA and TAA mRNA (i.n.) | Melanoma | NCT03394937 (I) | None | 2018 | Recruiting |
  Moderna TX Inc. | LNP-OX40L mRNA (i.t.) | Relapsed/refractory solid tumor malignancies or lymphoma, ovarian cancer | NCT03323398 (I/II, non-randomized) | Durvalumab | 2017 | Recruiting |
  Universitair Ziekenhuis Brussel, eTheRNA Immunotherapies Nv. | TriMix (CD70, CD40L, caTLR4) mRNA (i.t.) | Early resectable breast cancer | NCT03788083 (I) | None | 2018 | Recruiting |